We conducted a thorough study of Cu 2+ complex formation equilibria with Irbesartan and Losartan, the two primary drugs for the cure of cardiovascular diseases, with the aim of recognising if these drugs could exert a chelating action towards Cu
Introduction
Cardiovascular disease is the leading cause of death and disability in patients with diabetes (Go et al., 2013) . Defective copper regulation is widespread in diabetes, where it is likely one of the causes of cardiovascular disease, (Cooper et al., 2004) and is now serving as a target for experimental therapeutic intervention by treatment with a Cu 2+ -selective chelator (Cooper et al., 2009) . In diabetes, impaired copper regulation manifests as enhanced urinary Cu 2+ excretion, elevated systemic copper balance and defective myo-cellular copper regulation, (Cooper et al., 2004; Cooper et al., 2005; Zhang et al., 2014) and it has been involved in increased pro-oxidant stress, defective antioxidant defenses, (Lu et al., 2010) and progressive damage to the blood vessels, heart, kidneys and nerves (the 'diabetic complications') (Cooper, 2012) . Cardiovascular disease in diabetic patients tends to be more aggressive and disabling than in matched non-diabetic patients (Go et al., 2013; Kannel and McGhee, 1979) . A general opinion is that sartans exert their therapeutic effects through actions as angiotensin receptor blockers (ARBs). However, it is becoming increasingly apparent that, under certain circumstances, they may elicit some of their therapeutic effects through actions other than as ARBs. For example, Valsartan has been shown to improve arterial stiffness in type-2 diabetes independently of blood-pressurelowering, (Karalliedde et al., 2008) raising the possibility that it is acting through a different mechanism in this case. Notably, treatment with a Cu 2+ selective chelator improves diastolic stiffness and arterial fibrosis in animal models of diabetic cardiac and arterial disease (Lu et al., 2010; Zhang et al., 2013; Gong et al., 2006; Lu et al., 2013) . In the extra-cellular space, copper is present mainly in the form of Cu 2+ ions (Cooper, 2012) .
The present work takes origin from joint research efforts of two groups with different aims and expertise, a clinical group working on different aspect of diabetes, and a chemical group interested in metal complex formation of chelating agents for the treatment of metal ion toxicity. The working hypothesis is that some drugs in use in diabetic patients could also act as copper scavenging agents. Sartans share molecular properties with other clinically used Cu 2+ -binding molecules, such as triethylenetetramine, in use as a second line treatment for Wilson's disease and in the experimental therapeutics of the diabetic complications; (Cooper, 2011; Nurchi et al., 2013) both the two classes of molecules contain several nitrogen atoms spaced at distances consistent with potential Cu 2+ -binding sites (Fraústo da Silva and Williams, 2001; Massie et al., 2008; Lindholm et al., 2002 
Experimental

Reagents
Irbesartan and Potassium Losartan were purchased from TCI Europe. CuCl 2 , ZnCl 2 , NaOH, NaOD, NaCl, HCl, DCl, DMSO-d 6 , D 2 O, MeOD and methanol from Sigma Aldrich. All the reagents, analytical grade, were used without further purification.
Potentiometry
Protonation and complex formation equilibrium studies were carried out in a thermostatted glass cell equipped with a magnetic stirrer, under Argon flow. The potentiometric apparatus consisted in Metrohm 691 pH-meter, Dosimat 665 Metrohm titrator and Metrohm LL UNITRODE glass electrode. All the titrations were performed at 25.0°C using 0.1 M NaOH at ionic strength 0.1 M NaCl, in 30:70 and 80:20 MeOH/H 2 O mixtures. The electrode was daily calibrated for hydrogen ion concentration by HCl/NaOH titration in the same experimental conditions as above, and the results were analysed with Gran procedure (Gran, 1952) . Working ligand concentration was 0.5 mM both for protonation and for complex formation titrations. In the last case, 1:2 and 1:4 metal/ligand molar ratios were used. The obtained titration data were processed by Hyperquad 2013 program (Gans et al., 1996) .
Spectrophotometry
A Varian Cary 50 UV/Vis Spectrophotometer was used for UV-Visible studies. Ligand protonation equilibria were studied by titrating 20 mL of 0.5 mM ligand solutions with 0.1 M NaOH at 0.1 M NaCl ionic strength, in 30:70 and 80:20 MeOH/H 2 O mixtures, using a joined potentiometricspectrophotometric procedure (Nurchi et al., 2011) . Spectra were recorded in the 200-400 nm spectral range with a 0.2 cm path length fiber-optic probe. The obtained data were processed by HypSpec program . Solubility studies of ligand in water were made at pH 3 with the use of calibration curve previously prepared at the same conditions.
Spectrofluorimetry
A Varian Cary Fluorimeter was used for Fluorescence spectra. Ligand working concentrations for the study of protonation equilibria were 0.032 mM in 30:70 and 80:20 MeOD/H 2 O solutions. Batch measurements at variable pH were performed by adding proper amounts of HCl and NaOH. Since UV-Vis spectra at different pH values revealed an isosbestic point at 280 nm, this wavelength was chosen for 1 Potentiometric equilibrium studies are normally conducted in the 10 excitation. Emission spectra were registered in the 290-490 nm spectral range.
NMR
NMR measurements were performed on a Bruker Ascend™ 400 MHz spectrometer equipped with a 5 mm automated tuning and matching broadband probe with z-gradients, as previously described (Peana et al., 2013; Zoroddu et al., 2007; Zoroddu et al., 2010) . 5-7 mM concentrations of the ligands in different solvents, D 2 O, MeOD or DMSO at 25°C in 5 mm NMR tubes were used. The pH of the solutions was adjusted with diluted DCl and NaOD on a pH meter Crison micro TT 2050 with an electrode Mettler Toledo InLab 422. The pD values measured in D 2 O solutions were converted to the pH values by using the deuterium isotopic relation pH = pD -0.4 (Glasoe and Long, 1960; Covington et al., 1968) . A stock acidic deuterated aqueous solution of ZnCl2 salt was used to achieve the concentration of Zn 2+ ions. H TOCSYs were performed by using mixing times of 60 ms. A combination of 1D, 2D TOCSY, HSQC experiments was used to assign the signals of both free and metal-bound ligands at different pH values. All NMR data were processed with TopSpin software (Bruker Instruments) , and analysed by Sparky 3.11 and MestRe Nova 6.0.2 programs (Mestrelab Research S.L.).
ESI-MS
High-resolution mass spectra were obtained on a Bruker MicrO-TOF-Q spectrometer (Bruker Daltonik, Bremen, Germany) , equipped with an Apollo II electrospray ionization source and an ion funnel. The spectra were recorded in the positive ion mode in the range 100-1500 m/z. The instrument parameters were dry gas-nitrogen, temperature 200°C, ion source voltage 4500 V, collision energy 10 eV. Analyte aqueous solutions (0.1 mM) were introduced at a flow rate of 3 μL/min. Stock solutions were prepared by using MeOH/H 2 O mixture (50:50 v/v) as a solvent. The metal to ligand molar ratio was 1:2. The instrument was calibrated using the Tunemix mixture (BrukerDaltonik, Germany) in the quadratic regression mode. The overall charge of the analysed ion was calculated on the base of distance between isotopic peaks. Data were processed by Compass DataAnalysis 4.0 (Bruker Daltonik, Germany) program (Bruker, 2016) .
Speciation
All the calculations concerning the speciation were performed with HySS (Hyperquad Simulation and Speciation) program (Alderighi et al., 1999) . The details of the calculation procedure, the estimate of the concentration of zinc and copper in human plasma and of their interaction with albumin were described in depth in a previous paper .
An analysis of the pharmacokinetic behaviour of Irbesartan and Losartan was necessary in order to correlate the amount of chelating agent available in plasma at a given time with the amount of drug administered. In the work by Marino et al. (Marino et al., 1998) . Fig. 1 reports the Irbesartan concentrations (μg/ml) in plasma for the 24 h following administration, for different administered doses. From this plot it was possible to evaluate that Irbesartan concentration reaches a peak at 12 μM just before the 2 h, it is always N5 μM in the first 6 h. In the following 18 h before the next administration, the concentration slowly falls down to about 1 μM. 
Results and discussion
Ligand characterization
The acid-base behaviour of a drug is of great relevance in pharmacological sciences for its influence on bioavailability, activity and pharmacokinetics (Nurchi et al., 2016) . In particular, in the case of antihypertensive drugs, the knowledge of acid-base properties favours the comprehension of the physiological mechanisms in which their receptor antagonists are implied (Cagigal et al., 2001) . The charged protonated forms of lipophilic bases assume high relevance for the potential electrostatic interactions with anionic or zwitterionic lipids (Limbacher et al., 1985) . The value of the dissociation constants of habitually assumed cardiovascular drugs, increasingly formulated into controlled-release forms, is of great significance (Meloun et al., 2005) . The solubility of Losartan and Irbesartan strongly depends on the protonation state of the molecule, and their water solubility becomes extremely low at acidic pH. The aqueous solubility of Losartan (5.72 × 10 −5 M) and Irbesartan (4.64 × 10 −4 M) was spectrophotometrically determined at 280 nm at pH 3. At the pH of stomach, Irbes0artan is more soluble than Losartan, and this could be one of the reasons of the higher bioavailability of Irbesartan (60-80% (Gillis and Markham, 1997) ) than that of Losartan (33% (Goa and Wagstaff, 1996) ). Both Losartan and Irbesartan contain an acidic centre on the tetrazole ring, and a basic centre on the imidazole in the case of Losartan and on the 5-oxo-imidazole in Irbesartan. A number of dissociation (or protonation) constants related to this centers can be found in literature, but they do not mention neither the experimental conditions in which were determined, nor to the used techniques (Losartan 2.36 and 5.55 (McCarthy et al., 1998) , 4.9 (Williams et al., 1996) , 5.6 (Furtek and Lo, 1992) and Irbesartan 4.5 (Chang et al., 1997) ). Tosco et al. (Tosco et al., 2008) . presented reliable pKa values of both groups, potentiometrically evaluated in co-solvents of variable composition. These values, reported as a function of the percent composition allowed the extrapolation of the values in water and to compare these values with the corresponding ones of some tetrazole molecules (tetrazole 4.89, (Eicher and Hauptmann, 1995) methyltetrazole 5.50, (Ostrovskii et al., 1981) and 5-phenyl-1H tetrazole 4.38 (Haussen et al., 1970) ). These results remarked that the acidity of the tetrazole ring increases with aromatic 5-substitution, which implies a larger delocalization of the negative charge on the aromatic moiety, and the influence of the electron withdrawing substituent. Hence, the first dissociation was attributed to the imidazole ring and the second to the tetrazole ring (Tosco et al., 2008) .
Potentiometric results
Even if potentiometry and spectrophotometry represent the most suitable and handy techniques in the determination of equilibrium constants, the low water solubility of Irbesartan and Losartan at acidic pH prevented potentiometric studies in aqueous solution (Crisponi, 1997;  Aragoni et al., 1996) . Ligand dissociation studies were thus performed in methanol/water (MeOH/H 2 O) mixtures 30:70 and 80:20, being the effects of methanol on pK a values widely studied (Avdeef et al., 1993 Tosco et al. (Tosco et al., 2008) , the plots of pK a 's vs % of MeOH (Tosco et al., 2008) show that the higher the % of methanol, the lower pK a1 and the higher pK a2 . Indeed, the results in Table 1 present the same behaviour, except pK a2 of Irbesartan that has almost the same value at the two solvent compositions.
Spectrophotometric results
Irbesartan and Losartan are characterized by complex molecular structures, which allow monitoring spectrophotometrically the two protonation equilibria with close dissociation constants. The two molecules exhibit similar absorption bands, and we selected the spectral range from 240 to 310 nm, with an isosbestic point at~280 nm, as the most convenient for evaluating the dissociation constants.
The pK a values calculated with HypSpec program ) slightly differ from those potentiometrically determined (Table 1) and are less reliable. Actually, the low reliability depends on the small variations of t the absorptivity spectra with pKa (Fig. S14) .
Fluorescence results
The presence of the biphenyl and the imidazole fluorescent groups (fluorophores) allowed to collect the fluorescence spectra of both the ligands from pH 1 to 7 (Bridges et al., 1965; Jayabharathi et al., 2012) . In the pH range 1-2 the fluorescence peak shifts towards higher energy both in 30:70 and 80:20 MeOH/H 2 O solutions ( Fig. 1 and Fig. 2 ). In the pH range 2-7, upon excitation at 280 nm, both drugs show an emission band centered at 376 nm in 30:70 MeOH/H 2 O solution (Fig. 1B and Fig. 2B ), while this band is shifted to 370 nm in 80:20 MeOH/H 2 O (Fig. 1E and Fig. 2D ) due to the decreased polarity of the solvent.
In Fig. 3 , the fluorescence intensities at fixed wavelength are superimposed to the speciation plots obtained from the potentiometric results (Fig. 3) . The feature of these graphics indicates that the fluorescence emission is related to the deprotonation of imidazole ring. The mono-deprotonated LH ± species of Losartan is almost non-emissive, while only when the second deprotonation process starts a fluorescence quenching is observed in the case of Irbesartan. The quenching process is completed when the anionic form L − alone is present in solution. Fig. 3 shows that the fluorescence intensity of Irbesartan increases reaching a maximum at pH 3.6, then starts to decrease. On the contrary, the fluorescence intensity of Losartan, observable at acidic pH 2, progressively decreases vanishing at pH 5. A previous fluorescence study conducted in 5:95 MeOH/H 2 O solution gave evidence of only one dissociation equilibrium for each molecule, related to the tetrazole group, characterized by a pK a value 3.15 for Losartan and 4.70 for Irbesartan (Cagigal et al., 2001 1:2 and 1:4 metal/ligand molar ratios; at 1 mM ligand concentration the precipitation of the complex occurred. The results are reported in Table 2 . In the following we will indicate with I − and L − the completely deprotonated forms of Irbesartan and Losartan. Irbesartan and copper ions form a weak CuI 2 complex from pH 4, which loses two protons giving the [CuI 2 H −2 ] 2 − complex from pH 5 (Fig. 4A ). Zinc forms weaker complexes than copper, of the same stoichiometry (Fig. 4B , Table 2 ). The copper complexes with Losartan are slightly stronger than the complexes with Irbesartan (Table 2) . A 1:1 complex exists from pH 2.5, then replaced by variously protonated 1:2 complexes (Fig. 4C) . As previously, zinc complexes with Losartan are weaker than copper complexes, with the same stoichiometry (Fig. 4D) .
Copper complexes in 80:20 MeOH/H 2 O solution precipitate at pH N 5, while in the case of zinc complex precipitation occurs only at pH N 7. The formation of a neutral dimeric [Cu(Ligand) 2 (H 2 O) 3 ] 2 complex, previously synthesized and characterized, can explain the low solubility of copper complexes. FTIR and Raman studies gave evidence of copper coordination by tetrazole nitrogen atoms, and EPR measurements of the formation of a dimeric complex. The metal centers are in a tetragonal distorted environment. A monomeric complex was also found as a minor component (Etcheverry et al., 2007) .
Isothermal titration calorimetry showed that complexation in water occurs as a stepwise process, both enthalpy and entropy driven. 1:1 copper:Losartan complex forms at low molar ratio, and a 1:2 species is formed at molar ratios N 1 (Denadai et al., 2013) . This last 1:2 complex is enthalpically favored, due to the metal-ligand bond strengthened by Ligand Field Stabilization Energy. The loss of water molecules during complexation and the loss of complex molecular structure, due to tetragonal distortion, account for the entropic contribution. In the solid state, the formation of copper-active Van der Waals interactions between the aliphatic chains of Losartan stabilizes the copper complexes.
ESI-MS characterization of Cu
2+ and Zn 2+ complexes
Mass spectrometry is a potent complementary technique to support speciation studies, which allows determining the metal-to-ligand stoichiometry directly from the m/z values. We successfully employed ESI-MS for this purpose in previous works (Toso et al., 2013; Toso et al., 2014; Nurchi et al., 2014; Lachowicza et al., 2015; Lachowicz et al., 2015) .
ESI-MS measurements of Irbesartan and Losartan complexes with the bivalent copper and zinc cations confirms the findings of Denadai et al. (Denadai et al., 2013 Fig. 4 . Speciation plots relative of copper and zinc complexes calculated using the stability constants in Table 2 . Ligand concentration was 0.5 mM and a 1:2 metal to ligand ratio was used. Fig. 6 . ESI-MS spectra of Losartan A) pure, B) with copper at 1:1 molar ratio, and C) with zinc at 2:1 molar ratio in the 400-470 m/z range. 
NMR characterization of Zn 2+ complexes
The free Losartan ligand was studied by NMR techniques in the different solvents D 2 O at pH 7.0, MeOD-d4 and DMSO-d 6 (Fig. S15 and Table S1 ). The low solubility of Losartan in aqueous solution and the precipitation occurring after Zn 2+ addition (Losartan concentration 5-7 mM and Zn:L 1:2, 1:1 ratios) prevented the NMR study in water. Therefore, the interaction between Losartan and Zn 2+ was followed in (Sica et al., 2005) . E3174 was used as a step-product in the synthesis of 3-butyl-1-chloro-8-[2-(1H-tetrazol-5-yl)phenyl]-5,10-dihydroimidazo [1,5-b] isoquinoline, which is completely devoid of activity in the Angiotensin II receptor (Yoo et al., 1995) . Also in the case of Irbesartan, the spectra were acquired in MeOD solution, in which the ligand can be solved at the NMR used concentration. The 1 H 1D NMR spectrum and 1 H 2D COSY NMR spectra of aliphatic region were collected in MeOD solution (Figs. S16, S17 and Table S2 ). Perturbation in NMR spectra was observed in the Irbesartan methanolic when adding Zn 2+ ions. The 1 H 1D NMR spectra of free Irbesartan and in presence of Zn 2+ at a molar ratio Zn 2+ :Irbesartan 1:1 and 1:2 are presented in Fig. 10 . The most apparent feature is the total disappearance of the signal of the protons in position 7 in the aliphatic chain, and a change of the multiplicity of the signal of the two protons in position 8, as highlighted in the inset. A possible tautomerism induced by Zn 2+ ions, as reported in Scheme 3, can explain this behaviour. The signal of methylene proton in position 7 can then shift towards lower field, under the water signal.
Since only minor changes in chemical shifts are presented, upon Zn 2+ addition, by protons and carbons of tetrazole and biphenyl moieties, the coordination site of Zn 2+ ions can be mostly located on the imidazole ring of Irbesartan ligand.
Speciation studies
Based on the calculated protonation and complex formation constants of Irbesartan and Losartan a speciation study has been performed. An estimate of the total chelatable Cu 2+ and Zn 2+ circulating in plasma, and of their interaction with albumin, was previously presented . The estimate of available Irbesartan as a function of the time elapsed from its delivery is based on the work of Marino et al. (Marino et al., 1998) . The same estimates were used for Losartan assuming a similar behaviour. The micro molar concentrations of the formed complex species and the total complexed metal in percent with respect to the total metal are reported in Table 3 . It is apparent that in correspondence of the drug concentration peak and in all the first six hours from delivery the drug is able to effectively scavenge non-negligible amounts of copper, accompanied by lower amounts of zinc. These results cannot be assumed as a quantitative evaluation of the real behaviour of the drug in vivo for the rough approximations necessarily assumed, as well as for the possible involvement of different copper pools accessible to the drug other than plasma. Nevertheless, they are indicative of a trend in the scavenging activity of the drugs. Furthermore, it must be remembered that the interaction between the drug and the metal ions is not only dictated by the thermodynamic properties, but that also the kinetic factors can play an important role in determining the behaviour of the system.
Conclusions
The use of different complementary techniques has allowed both to give the protonation and complex formation constants of Irbesartan and Losartan with Cu 2+ and Zn 2+ , and to attribute the protonation :Irbesartan system in MeOD-d 4 solvent at a molar ratio of 0:1 (red), 1:2 (green) and 1:1(blue) at 25°C and pH 7.
Scheme 3. Possible tautomerism induced by Zn 2+ ions.
sequence and the coordination sites. The presence of variously protonated species also explains the fluorescence behaviour of both drugs.
In particular, the binding of both metal ions through the tetrazole moiety obtained clear evidence, except in the case of the Zn 2+ / Irbesartan system. In this case, NMR measurements give evidence of a possible tautomerism involving the imidazole ring and the connected aliphatic chain. The possibility to form tautomers in the case of Irbesartan might also explain the differences observed in the luminescence properties of the two drugs. ESI-MS spectra remark that in the 1:1 Zn 2+ /Irbesartan complex one or two water molecules are present. The speciation study, even in the remarked restraints of the made assumption, gives a realistic indication of a copper scavenging action of the two drugs, deserving further clinical attention. 
